Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock
December 12 2019 - 8:00AM
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the
pricing of its underwritten public offering of 14,516,130 shares of
its common stock at the public offering price of $15.50 per share
for total gross proceeds to Momenta of approximately $225.0
million. Momenta has granted the underwriters an option to purchase
up to an additional 2,177,419 shares of its common stock,
exercisable for 30 days.
Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint
lead book-running managers for the offering. Stifel is acting as a
book-running manager for the offering.
The offering is being made pursuant to an effective shelf
registration statement on Form S-3 that was filed with the U.S.
Securities and Exchange Commission (SEC) on August 8, 2019. A
preliminary prospectus supplement describing the terms of the
offering has been filed with the SEC and forms a part of the
effective registration statement. A final prospectus supplement
will be filed with the SEC and will form a part of the effective
registration statement. Copies of the final prospectus supplement
and accompanying prospectus relating to this offering may be
obtained, when available, by contacting Goldman Sachs & Co.
LLC, Attention: Prospectus Department, 200 West Street, New York,
NY 10282, or by telephone: (866) 471-2526, facsimile: (212)
902-9316 or by emailing prospectus-ny@ny.email.gs.com; J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, or by telephone: (866) 803-9204;
or Stifel, Nicolaus & Company, Incorporated, Attention:
Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA
94104, or by telephone: (415) 364-2720 or by emailing
syndprospectus@stifel.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of
shares of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Momenta
Momenta Pharmaceuticals is a biotechnology company with a
validated innovative scientific platform focused on discovering and
developing novel therapeutics to treat rare, immune-mediated
diseases and advancing its late stage biosimilar portfolio. The
company is headquartered in Cambridge, MA.
Forward Looking Statements
Statements in this press release regarding future expectations,
beliefs, intentions, goals, strategies, plans or prospects, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, statements about the filing and availability of a final
prospectus supplement. Forward-looking statements may be identified
by words such as “believe,” “continue,” “plan to,” “potential,”
“will,” and other similar words or expressions, or the negative of
these words or similar words or expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other
important factors, including those referred to under the section
“Risk Factors” in the Company's Quarterly Report on Form 10-Q for
the quarter ended September 30, 2019 filed with the Securities and
Exchange Commission, as well as other documents that may be filed
by the Company from time to time with the Securities and Exchange
Commission. As a result of such risks, uncertainties and factors,
the Company’s actual results may differ materially from any future
results, performance or achievements discussed in or implied by the
forward-looking statements contained herein. The Company is
providing the information in this press release as of this date and
assumes no obligations to update the information included in this
press release or revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
INVESTOR CONTACT:Patty
EisenhaurMomenta
Pharmaceuticals1-617-395-5189IR@momentapharma.com |
MEDIA CONTACT:Karen
SharmaMacDougall 1-781-235-3060Momenta@macbiocom.com |
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024